+1.04%
Today
Loading 1D prices…
Company profile
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
Sector
Health Care
Industry
Surgical & Medical Instruments & Apparatus
Exchange
Nasdaq
Display currency
USD
Location
Baar, United States
Employees
1.6K
Fiscal year end
1231
CIK
1645113
Session & valuation
Latest annual period
Deterministic peer set
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| LMATLeMaitre Vascular Inc. Common Stock | $1.8B | $249.6M | +23.12% | $2.52 | +2.27% | Hold |
| ATECAlphatec Holdings Inc. Common Stock | $1.6B | $764.2M | -18.76% | -$0.96 | +19.80% | Buy |
| INSPInspire Medical Systems Inc. Common Stock | $2.1B | $912M | +15.95% | $4.89 | +7.16% | Hold |
| UFPTUFP Technologies Inc. Common Stock | $2.2B | $602.8M | +11.33% | $8.75 | +0.18% | Hold |
| KMTSKestra Medical Technologies Ltd. Common Stock | $1.3B | $95.1M | -138.36% | -$2.43 | -3.05% | Buy |